<DOC>
	<DOCNO>NCT01386112</DOCNO>
	<brief_summary>Eosinophilic esophagitis ( EoE ) inflammatory disease esophagus , characterize eosinophilic infiltration gastrointestinal ( GI ) symptom . There pharmacological treatment EoE approve US Food Drug Administration ( FDA ) . Supported published case series control trial child adult , widely use drug treatment EoE off-label use corticosteroid intend local ( esophageal mucosal ) action . This study evaluate safety tolerability orally administer EUR-1100 twice daily . Eligible subject randomize one 3 treatment group . The Treatment Period 8 week subject visit clinic screen visit , randomization , week 4 , 8 1 week end treatment clinical symptom assessment safety evaluation . Additional phone visit occur week 2 week 6 .</brief_summary>
	<brief_title>Safety Tolerability Study Oral EUR-1100 Treat Eosinophilic Esophagitis</brief_title>
	<detailed_description />
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<criteria>Key Male female subject age ≥ 12 ≤ 55 year ; Written inform consent ( parent guardian must sign applicable ) assent form , require ; Evidence eosinophilic esophagitis define esophageal mucosal eosinophil count great equal 24 per HPF ( 400x magnification ) least 1 esophageal site biopsied ( proximal/middle and/or distal ) ; Lack histological response previously administer high dose proton pump inhibitor ; Clinical symptom eosinophilic esophagitis least one follow symptom : chest pain discomfort , dysphagia ( difficulty swallow ) food impaction . Key Known contraindication , hypersensitivity intolerance corticosteroid ; Any physical , mental , social condition , history illness laboratory abnormality , investigator 's judgment , might interfere study procedure ability subject adhere complete study ; Oral esophageal mucosal infection type ; Any condition affect esophageal mucosa alter esophageal motility EoE ; Use systemic ( oral parenteral ) inhale , intranasal highpotency dermal topical corticosteroid 30 day prior esophageal biopsy require entrance study ( prior EGD do preScreening period ) time biopsy Randomization Visit ; Adrenal suppression ; Any medical condition use antiinflammatory immunosuppressant drug require may anticipate required study ; Contraindication EGD esophageal biopsy narrow esophagus preclude EGD ; History esophageal gastric surgery ( history esophageal dilatation allow ) ; Gastrointestinal bleeding ; Current chronic infection , immunosuppression , immunodeficiency ; History presence Crohn 's disease , celiac disease , inflammatory disease gastrointestinal tract ; Alcohol drug abuse ; Female subject pregnant breastfeeding ; Participation clinical study involve investigational drug within 30 day Screening Visit .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>